VRTX EBITDA | VERTEX PHARMACEUTICALS INC / MA

VERTEX PHARMACEUTICALS INC / MA (VRTX) EBITDA

2026-06-30: Basis Reported; EBITDA $1.3B; Operating income (m); Depreciation and amortization (m).
2026-03-31: Basis Reported; EBITDA $1.19B; Operating income (m); Depreciation and amortization (m).
2025-12-31: Basis Reported; EBITDA $1.26B; Operating income (m); Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA $1.24B; Operating income (m); Depreciation and amortization (m).

Complete source-backed ebitda history.

Available history: 2008-12-31 to 2026-06-30
Data captured: 2026-09-04

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	$1.3B	(m)	(m)	(m)	39.10%	$112.20M*	$1.13B*	$489.20M	(m)	$582.20M	$292.00M
2026-03-31	Reported	$1.19B	(m)	(m)	(m)	39.97%	$133.40M	$1.43B	$392.80M	(m)	$493.70M	$221.50M
2025-12-31	Reported	$1.26B	(m)	(m)	(m)	39.55%	(m)	(m)	(m)	(m)	(m)	(m)
2025-09-30	Reported	$1.24B	(m)	(m)	(m)	40.31%	$101.80M*	$1.24B*	$414.80M	(m)	$445.10M	$215.90M
2025-06-30	Reported	$1.2B	(m)	(m)	(m)	40.57%	$145.70M*	$1.07B*	$407.50M	(m)	$424.60M	$250.10M
2025-03-31	Reported	$678.5M	(m)	(m)	(m)	24.49%	$40.70M	$818.90M	$363.00M	(m)	$396.40M	$84.10M
2024-12-31	Reported	$1.07B	(m)	(m)	(m)	36.83%	(m)	(m)	(m)	(m)	(m)	(m)
2024-09-30	Reported	$1.17B	(m)	(m)	(m)	42.19%	$67.70M*	$1.37B*	$392.60M	(m)	$371.80M	$178.70M
2024-06-30	Reported	-$3.46B	(m)	(m)	(m)	-130.81%	$69.00M*	-$3.75B*	$371.90M	(m)	$372.20M	$202.40M
2024-03-31	Reported	$1.19B	(m)	(m)	(m)	44.34%	$68.40M	$1.31B	$342.60M	(m)	$342.70M	$179.50M
2023-12-31	Reported	$1.05B	(m)	(m)	(m)	41.61%	(m)	(m)	(m)	(m)	(m)	(m)
2023-09-30	Reported	$1.08B*	$1.04B	$42.10M*	$2.48B	43.50%*	$40.60M*	$1.27B*	$318.70M	(m)	$263.80M	$143.90M
2023-06-30	Reported	$1.07B*	$1.03B	$41.40M*	$2.49B	42.83%*	$59.60M*	$1.13B*	$308.60M	(m)	$262.60M	$245.80M
2023-03-31	Reported	$817.8M	(m)	(m)	(m)	34.44%	$42.10M	$899.90M	$266.90M	(m)	$241.10M	$191.70M
2022-12-31	Reported	$1.07B	(m)	(m)	(m)	46.55%	(m)	(m)	(m)	(m)	(m)	(m)
2022-09-30	Reported	$1.16B*	$1.13B	$36.70M*	$2.33B	49.84%*	$54.20M*	$955.50M*	$289.40M	(m)	$246.80M	$245.90M
2022-06-30	Reported	$1.14B*	$1.11B	$37.30M*	$2.20B	52.07%*	$53.30M*	$1.14B*	$261.80M	(m)	$215.30M	$213.90M
2022-03-31	Reported	$1.08B	(m)	(m)	(m)	51.34%	$63.60M	$956.20M	$245.80M	$603.10M	$215.20M	$192.70M
2021-12-31	Reported	$911.5M	(m)	(m)	(m)	43.98%	(m)	(m)	(m)	(m)	(m)	(m)
2021-09-30	Reported	$1.09B*	$1.05B	$31.70M*	$1.98B	54.75%*	$52.40M*	$927.20M*	$236.50M	$493.75M	$198.20M	$230.90M
2021-06-30	Reported	-$6.60M*	-$37.90M	$31.30M*	$1.79B	-0.37%*	$49.90M*	-$199.70M*	$228.00M	$1.41B	$194.60M	-$111.20M
2021-03-31	Reported	$916.6M	(m)	(m)	(m)	53.16%	$70.90M	$921.00M	$192.30M	$456.00M	$192.10M	$167.80M
2020-12-31	Reported	$775.14M	(m)	(m)	(m)	47.62%	(m)	(m)	$203.10M	$466.58M	$211.84M	$284.43M
2020-09-30	Reported	$698.88M*	$672.24M	$26.64M*	$1.54B	45.43%*	$174.79M*	$907.75M*	$186.18M	$493.50M	$184.55M	$78.44M
2020-06-30	Reported	$744.73M*	$718.03M	$26.70M*	$1.52B	48.85%*	$17.86M*	$1.04B*	$184.52M	$420.93M	$191.80M	-$12.50M
2020-03-31	Reported	$747.05M	(m)	(m)	(m)	49.31%	$19.45M	$815.70M	$162.50M	$448.53M	$182.26M	$54.78M
2019-12-31	Reported	$577.61M	(m)	(m)	(m)	40.87%	(m)	(m)	$185.01M	$480.01M	$195.28M	$93.72M
2019-09-30	Reported	$125.18M*	$99.33M	$25.85M*	$949.83M	13.18%*	$24.29M*	$334.79M*	$131.91M	$555.95M	$159.67M	$13.15M
2019-06-30	Reported	$297.66M*	$269.96M	$27.70M*	$941.29M	31.62%*	$16.36M*	$463.75M*	$135.74M	$379.09M	$156.50M	$59.71M
2019-03-31	Reported	$303.95M	(m)	(m)	(m)	35.41%	$18.04M	$324.78M	$95.09M	$339.49M	$147.04M	$51.53M
2018-12-31	Reported	$146.55M	(m)	(m)	(m)	16.84%	(m)	(m)	$122.29M	$437.88M	$153.21M	-$1.49B
2018-09-30	Reported	$224.84M*	$205.65M	$19.19M*	$784.53M	28.66%*	$20.91M*	$381.35M*	$111.25M	$330.51M	$137.29M	$8.05M
2018-06-30	Reported	$190.94M*	$172.88M	$18.06M*	$752.16M	25.39%*	$29.61M*	$321.70M*	$104.38M	$337.53M	$137.30M	$10.34M
2018-03-31	Reported	$145.24M	(m)	(m)	(m)	22.67%	$29.28M	$252.66M	$71.61M	$310.55M	$129.81M	-$12.66M
2017-12-31	Reported	$142.17M	(m)	(m)	(m)	21.82%	(m)	(m)	$84.05M	$306.66M	$134.79M	$10.26M
2017-09-30	Reported	-$310.82M*	-$326.04M	$15.22M*	$578.16M	-53.76%*	$27.96M*	$170.09M*	$72.87M	$454.95M	$120.71M	-$125.90M
2017-06-30	Reported	$67.60M*	$52.71M	$14.89M*	$544.13M	12.42%*	$17.38M*	$181.65M*	$71.20M	$289.45M	$127.25M	$4.34M
2017-03-31	Reported	$285.69M	(m)	(m)	(m)	39.97%	$11.10M	$265.69M	$46.99M	$273.56M	$113.33M	$3.98M
2016-12-31	Reported	$55.09M	(m)	(m)	(m)	12.01%	(m)	(m)	(m)	$248.45M	$109.91M	-$7.45M
2016-09-30	Reported	-$4.16M*	-$18.73M	$14.57M*	(m)	(m)	$13.88M*	$65.66M*	(m)	$272.37M	$106.06M	$503.00K
2016-06-30	Reported	$18.32M*	$3.35M	$14.96M*	(m)	(m)	$15.92M*	$40.86M*	(m)	$271.01M	$111.65M	$18.13M
2016-03-31	Reported	$2.09M	(m)	(m)	(m)	0.52%	$11.97M	-$15.14M	(m)	$255.86M	$105.21M	$5.49M
2015-12-31	Reported	-$37.96M	(m)	(m)	(m)	-9.08%	(m)	(m)	(m)	$310.18M	$96.55M	-$1.38M
2015-09-30	Reported	-$53.86M*	-$70.03M	$16.17M*	(m)	(m)	$8.80M*	-$62.07M*	(m)	$246.28M	$99.77M	$1.33M
2015-06-30	Reported	-$157.10M*	-$171.16M	$14.06M*	(m)	(m)	$13.42M*	-$110.27M*	(m)	$223.86M	$94.39M	$30.13M
2015-03-31	Reported	-$155.62M	(m)	(m)	(m)	-112.36%	$10.56M	-$222.24M	(m)	$215.60M	$85.86M	$299.00K
2014-12-31	Reported	-$137.29M	(m)	(m)	(m)	-94.97%	(m)	(m)	(m)	$201.46M	$78.53M	$2.04M
2014-09-30	Reported	-$125.24M*	-$142.20M	$16.96M*	(m)	(m)	$9.30M*	-$87.65M*	(m)	$190.94M	$75.22M	$3.42M
2014-06-30	Reported	-$166.37M*	-$180.54M	$14.17M*	(m)	(m)	$11.70M*	-$127.92M*	(m)	$224.49M	$77.45M	$693.00K
2014-03-31	Reported	-$200.25M	(m)	(m)	(m)	-169.06%	$15.53M	-$175.76M	(m)	$238.62M	$74.21M	$803.00K
2013-12-31	Reported	$7.35M	(m)	(m)	(m)	2.09%	(m)	(m)	(m)	$238.46M	$73.06M	$1.35M
2013-09-30	Reported	-$114.07M*	-$123.56M	$9.49M*	(m)	(m)	$18.51M*	-$13.72M*	(m)	$219.44M	$86.43M	$2.56M
2013-06-30	Reported	-$36.48M*	-$47.03M	$10.55M*	(m)	(m)	$1.80M*	-$927.00K*	(m)	$213.99M	$105.08M	$558.00K
2013-03-31	Reported	-$427.6M	(m)	(m)	(m)	-130.22%	$16.61M	-$65.78M	(m)	$210.20M	$91.63M	-$126.89M
2012-12-31	Reported	-$20.71M	(m)	(m)	(m)	-6.20%	(m)	(m)	(m)	$213.11M	$110.45M	-$2.70M
2012-09-30	Reported	$7.52M*	-$1.07M	$8.59M*	(m)	(m)	$21.40M*	$105.96M*	(m)	$200.16M	$97.68M	$21.36M
2012-06-30	Reported	-$2.10M*	-$10.77M	$8.66M*	(m)	(m)	$15.54M*	$118.41M*	(m)	$196.54M	$117.51M	$20.06M
2012-03-31	Reported	$100.21M	(m)	(m)	(m)	22.84%	$6.16M	$2.92M	(m)	$196.37M	$111.15M	$32.00K
2011-12-31	Reported	$233.63M	(m)	(m)	(m)	41.47%	(m)	(m)	(m)	$186.44M	$121.88M	$22.66M
2011-09-30	Reported	$223.46M*	$215.71M	$7.75M*	(m)	(m)	$9.98M*	(m)	(m)	$189.05M	$110.65M	-$27.84M
2011-06-30	Reported	-$157.18M*	-$165.89M	$8.71M*	(m)	(m)	$10.43M*	-$216.19M*	(m)	$173.60M	$96.66M	$24.45M
2011-03-31	Reported	-$151.04M	(m)	(m)	(m)	-205.05%	$4.85M	-$186.63M	(m)	$158.61M	$71.52M	$0.00
2010-12-31	Reported	-$158.43M	(m)	(m)	(m)	-241.79%	(m)	(m)	(m)	$168.89M	$62.48M	(m)
2010-09-30	Reported	-$192.83M*	-$199.59M	$6.76M*	(m)	(m)	$10.83M*	-$163.99M*	(m)	$170.43M	$48.85M	(m)
2010-06-30	Reported	-$161.66M*	-$169.57M	$7.91M*	(m)	(m)	$9.69M*	-$108.89M*	(m)	$155.08M	$40.91M	(m)
2010-03-31	Reported	-$152.7M	(m)	(m)	(m)	-680.81%	$3.11M	-$196.46M	(m)	$143.01M	$35.55M	(m)
2009-12-31	Reported	-$138.34M	(m)	(m)	(m)	-408.20%	(m)	(m)	(m)	$135.23M	$32.57M	(m)
2009-09-30	Reported	-$141.42M*	-$148.23M	$6.82M*	(m)	(m)	$4.75M*	-$21.64M*	(m)	$132.13M	$36.57M	(m)
2009-06-30	Reported	-$149.42M*	-$157.17M	$7.75M*	(m)	(m)	$4.59M*	-$118.06M*	(m)	$139.33M	$32.53M	(m)
2009-03-31	Reported	-$154.73M	(m)	(m)	(m)	-645.27%	$6.58M	-$185.56M	(m)	$143.58M	$28.52M	(m)

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	$4.38B	(m)	(m)	(m)	36.52%	$437.60M	$3.63B	$1.65B	(m)	$1.75B	$690.00M
2024-12-31	Reported	-$25.7M	(m)	(m)	(m)	-0.23%	$297.70M	-$492.60M	$1.53B	(m)	$1.46B	$784.10M
2023-12-31	Reported	$4.01B	(m)	(m)	(m)	40.66%	$200.40M	$3.54B	$1.26B	(m)	$1.14B	$760.20M
2022-12-31	Reported	$4.46B	(m)	(m)	(m)	49.89%	$204.70M	$4.13B	$1.08B	(m)	$944.70M	$910.40M
2021-12-31	Reported	$2.91B	(m)	(m)	(m)	38.39%	$235.00M	$2.64B	$904.20M	$3.05B	$840.10M	$388.30M
2021-09-30	Rolling	(m)	$2.65B*	(m)	$7.13B*	(m)	(m)	(m)	$859.90M*	$2.82B*	$796.74M*	$571.93M*
2021-06-30	Rolling	(m)	$2.27B*	(m)	$6.68B*	(m)	(m)	(m)	$809.58M*	$2.82B*	$783.09M*	$419.47M*
2021-03-31	Rolling	(m)	$3.02B*	(m)	$6.41B*	(m)	(m)	(m)	$766.10M*	$1.84B*	$780.30M*	$518.17M*
2020-12-31	Reported	$2.97B	(m)	(m)	(m)	47.79%	$259.80M	$3.25B	$736.30M	$1.83B	$770.50M	$405.20M
2020-12-31	Rolling	(m)	$2.86B*	(m)	$6.21B*	(m)	(m)	(m)	$736.30M*	$1.83B*	$770.46M*	$405.15M*
2020-09-30	Rolling	(m)	$2.66B*	(m)	$5.99B*	(m)	(m)	(m)	$718.21M*	$1.84B*	$753.89M*	$214.43M*
2020-06-30	Rolling	(m)	$2.09B*	(m)	$5.40B*	(m)	(m)	(m)	$663.94M*	$1.91B*	$729.01M*	$149.15M*
2020-03-31	Rolling	(m)	$1.64B*	(m)	$4.82B*	(m)	(m)	(m)	$615.16M*	$1.86B*	$693.71M*	$221.36M*
2019-12-31	Reported	$1.3B	(m)	(m)	(m)	31.33%	$75.40M	$1.57B	$547.80M	$1.75B	$658.50M	$218.10M
2019-12-31	Rolling	(m)	$1.20B*	(m)	$4.16B*	(m)	(m)	(m)	$547.76M*	$1.75B*	$658.50M*	$218.11M*
2019-09-30	Rolling	(m)	$773.82M*	(m)	$3.62B*	(m)	(m)	(m)	$485.04M*	$1.71B*	$616.43M*	-$1.37B*
2019-06-30	Rolling	(m)	$880.14M*	(m)	$3.45B*	(m)	(m)	(m)	$464.38M*	$1.49B*	$594.05M*	-$1.37B*
2019-03-31	Rolling	(m)	$783.06M*	(m)	$3.27B*	(m)	(m)	(m)	$433.02M*	$1.45B*	$574.85M*	-$1.42B*
2018-12-31	Reported	$707.57M	(m)	(m)	(m)	23.22%	$95.45M	$1.27B	$409.54M	$1.42B	$557.62M	-$1.49B
2018-12-31	Rolling	(m)	$635.15M*	(m)	$3.05B*	(m)	(m)	(m)	$409.54M*	$1.42B*	$557.62M*	-$1.49B*
2018-09-30	Rolling	(m)	$633.16M*	(m)	$2.83B*	(m)	(m)	(m)	$371.30M*	$1.29B*	$539.20M*	$15.99M*
2018-06-30	Rolling	(m)	$101.47M*	(m)	$2.62B*	(m)	(m)	(m)	$332.92M*	$1.41B*	$522.62M*	-$117.96M*
2018-03-31	Rolling	(m)	-$18.70M*	(m)	$2.41B*	(m)	(m)	(m)	$299.74M*	$1.36B*	$512.56M*	-$123.97M*
2017-12-31	Reported	$184.64M	(m)	(m)	(m)	7.42%	$99.42M	$844.94M	$275.12M	$1.32B	$496.08M	-$107.32M
2017-12-31	Rolling	(m)	$123.24M*	(m)	$2.49B*	(m)	(m)	(m)	$275.12M*	$1.32B*	$496.08M*	-$107.32M*
2017-09-30	Rolling	(m)	$37.15M*	(m)	(m)	(m)	(m)	(m)	(m)	$1.27B*	$471.19M*	-$125.03M*
2017-06-30	Rolling	(m)	$344.46M*	(m)	(m)	(m)	(m)	(m)	(m)	$1.08B*	$456.54M*	$1.37M*
2017-03-31	Rolling	(m)	$295.11M*	(m)	(m)	(m)	(m)	(m)	(m)	$1.07B*	$440.94M*	$15.16M*
2016-12-31	Reported	$71.33M	(m)	(m)	(m)	4.19%	$56.56M	$236.10M	$210.46M	$1.05B	$432.83M	$16.66M
2016-12-31	Rolling	(m)	$9.94M*	(m)	(m)	(m)	(m)	(m)	(m)	$1.05B*	$432.83M*	$16.66M*
2016-09-30	Rolling	(m)	-$83.41M*	(m)	(m)	(m)	(m)	(m)	(m)	$1.11B*	$419.47M*	$22.74M*
2016-06-30	Rolling	(m)	-$134.71M*	(m)	(m)	(m)	(m)	(m)	(m)	$1.08B*	$413.19M*	$23.57M*
2016-03-31	Rolling	(m)	-$309.22M*	(m)	(m)	(m)	(m)	(m)	(m)	$1.04B*	$395.93M*	$35.57M*
2015-12-31	Reported	-$404.54M	(m)	(m)	(m)	-39.19%	$45.30M	-$365.43M	(m)	$995.92M	$376.57M	$30.38M
2015-12-31	Rolling	(m)	-$466.88M*	(m)	(m)	(m)	(m)	(m)	(m)	$995.92M*	$376.57M*	$30.38M*
2015-09-30	Rolling	(m)	-$566.80M*	(m)	(m)	(m)	(m)	(m)	(m)	$887.20M*	$358.55M*	$33.80M*
2015-06-30	Rolling	(m)	-$638.98M*	(m)	(m)	(m)	(m)	(m)	(m)	$831.86M*	$334.00M*	$35.89M*
2015-03-31	Rolling	(m)	-$648.36M*	(m)	(m)	(m)	(m)	(m)	(m)	$832.49M*	$317.06M*	$6.45M*
2014-12-31	Reported	-$629.16M	(m)	(m)	(m)	-108.40%	$51.20M	-$573.11M	(m)	$855.51M	$305.41M	$6.96M
2014-12-31	Rolling	(m)	-$692.41M*	(m)	(m)	(m)	(m)	(m)	(m)	$855.51M*	$305.41M*	$6.96M*
2014-09-30	Rolling	(m)	-$549.07M*	(m)	(m)	(m)	(m)	(m)	(m)	$892.50M*	$299.94M*	$6.27M*
2014-06-30	Rolling	(m)	-$530.42M*	(m)	(m)	(m)	(m)	(m)	(m)	$921.01M*	$311.14M*	$5.40M*
2014-03-31	Rolling	(m)	-$396.91M*	(m)	(m)	(m)	(m)	(m)	(m)	$910.51M*	$338.77M*	$5.27M*
2013-12-31	Reported	-$561.64M	(m)	(m)	(m)	-46.34%	$51.39M	-$60.67M	(m)	$882.10M	$356.19M	-$122.42M
2013-12-31	Rolling	(m)	-$610.01M*	(m)	(m)	(m)	(m)	(m)	(m)	$882.10M*	$356.19M*	-$122.42M*
2013-09-30	Rolling	(m)	-$677.20M*	(m)	(m)	(m)	(m)	(m)	(m)	$856.75M*	$393.58M*	-$126.47M*
2013-06-30	Rolling	(m)	-$554.72M*	(m)	(m)	(m)	(m)	(m)	(m)	$837.46M*	$404.84M*	-$107.67M*
2013-03-31	Rolling	(m)	-$518.46M*	(m)	(m)	(m)	(m)	(m)	(m)	$820.01M*	$417.27M*	-$88.17M*
2012-12-31	Reported	$84.92M	(m)	(m)	(m)	5.56%	$71.14M	$267.84M	(m)	$765.90M	$432.68M	-$275.00K
2012-12-31	Rolling	(m)	$2.33M*	(m)	(m)	(m)	(m)	(m)	(m)	$806.18M*	$436.80M*	$38.75M*
2012-09-30	Rolling	(m)	$303.71M*	(m)	(m)	(m)	(m)	(m)	(m)	$779.51M*	$448.23M*	$64.11M*
2012-06-30	Rolling	(m)	$520.49M*	(m)	(m)	(m)	(m)	(m)	(m)	$768.40M*	$461.19M*	$14.91M*
2012-03-31	Rolling	(m)	$365.37M*	(m)	(m)	(m)	(m)	(m)	(m)	$745.47M*	$440.34M*	$19.30M*
2011-12-31	Reported	$148.86M	(m)	(m)	(m)	10.55%	$34.59M	$143.74M	(m)	$707.71M	$400.72M	$19.27M
2011-12-31	Rolling	(m)	$113.82M*	(m)	(m)	(m)	(m)	(m)	(m)	$707.71M*	$400.72M*	$19.27M*
2011-09-30	Rolling	(m)	-$276.72M*	(m)	(m)	(m)	(m)	(m)	(m)	$690.16M*	$341.32M*	(m)
2011-06-30	Rolling	(m)	-$692.01M*	(m)	(m)	(m)	(m)	(m)	(m)	$671.54M*	$279.52M*	(m)
2011-03-31	Rolling	(m)	-$695.69M*	(m)	(m)	(m)	(m)	(m)	(m)	$653.02M*	$223.77M*	(m)
2010-12-31	Reported	-$665.62M	(m)	(m)	(m)	-464.27%	$38.05M	-$635.44M	(m)	$637.42M	$187.80M	$0.00
2010-12-31	Rolling	(m)	-$696.08M*	(m)	(m)	(m)	(m)	(m)	(m)	$637.42M*	$187.80M*	(m)
2010-09-30	Rolling	(m)	-$676.16M*	(m)	(m)	(m)	(m)	(m)	(m)	$603.76M*	$157.90M*	(m)
2010-06-30	Rolling	(m)	-$624.81M*	(m)	(m)	(m)	(m)	(m)	(m)	$565.46M*	$145.61M*	(m)
2010-03-31	Rolling	(m)	-$612.40M*	(m)	(m)	(m)	(m)	(m)	(m)	$549.71M*	$137.22M*	(m)
2009-12-31	Reported	-$583.91M	(m)	(m)	(m)	-573.08%	$23.50M	-$427.59M	(m)	$550.27M	$130.19M	(m)
2009-12-31	Rolling	(m)	-$614.01M*	(m)	(m)	(m)	(m)	(m)	(m)	$550.27M*	$130.19M*	(m)
2008-12-31	Reported	-$430.51M	(m)	(m)	(m)	-245.30%	$32.18M	-$226.48M	(m)	$516.91M	$101.29M	(m)

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
BRISTOL MYERS SQUIBB CO (BMY)	United States	$125.637B	12.67
PFIZER INC (PFE)	United States	$162.042B	31.94
ABBOTT LABORATORIES (ABT)	United States	$176.045B	28.47
REGENERON PHARMACEUTICALS, INC. (REGN)	United States	$74.751B	21.53
ALNYLAM PHARMACEUTICALS, INC. (ALNY)	United States	$33.420B	54.94
Zoetis Inc. (ZTS)	United States	$29.045B	11.38
INSMED Inc (INSM)	United States	$26.566B	-26.60
Roivant Sciences Ltd. (ROIV)		$26.105B	-96.08
Royalty Pharma plc (RPRX)	United States	$22.628B
UNITED THERAPEUTICS Corp (UTHR)	United States	$20.249B	17.64